June 08, 2022

Alicia Batts Addresses FTC Probe Into Pharmacy Benefit Management in Law360

Law360 turned to antitrust partner Alicia Batts for her commentary on the potential impact of a recent probe by the Federal Trade Commission (FTC) on the pharmacy benefit management (PBM) industry.

Batts said the FTC increased its focus on pharmaceuticals and PBMs as a result of President Biden signing an executive order seeking to invigorate competition across the American economy, especially with regard to prescription drugs. “Now that there is a full commission, the pharmaceutical industry should anticipate more FTC scrutiny,” she stated.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.